Physician profile
Patrick Spence
NPI 1548504624
$6,497.60
in general payments reported to CMS, 2019-2025
29 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $1,060 · 2023: $2,834 · 2024: $861 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,532 · Consulting Fee: $1,570 · Travel and Lodging: $29.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.04 |
| Consulting Fee | $1,570.00 |
| Travel and Lodging | $29.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,095.24 | 2021-2025 | Yeztugo, Biktarvy |
| Viiv Healthcare Company | $934.64 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $562.50 | 2021-2025 | |
| Novo Nordisk INC | $245.75 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Products, Lp | $224.39 | 2022-2023 | Symtuza |
| Lilly USA, LLC | $170.08 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $168.17 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Stryker Corporation | $159.38 | 2022 | |
| Merck Sharp & Dohme LLC | $154.52 | 2022-2025 | Pifeltro, Gardasil 9, Delstrigo |
| Exact Sciences Corporation | $132.81 | 2024-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $102.66 | 2022-2023 | Symtuza |
| Napo Pharmaceuticals INC | $90.00 | 2023-2025 | Mytesi |
| Bayer Healthcare Pharmaceuticals INC. | $66.06 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.52 | 2022-2023 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $40.62 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.33 | 2022-2023 | Xifaxan |
| Shionogi INC | $29.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.97 | 2024 | Eliquis |
| Verity Pharmaceuticals INC. | $21.35 | 2024 | Tlando |
| Amgen INC. | $20.15 | 2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $20.00 | 2023 | Shingrix |
| Astellas Pharma US INC | $19.66 | 2024 | Veozah |
| Emd Serono, INC. | $18.66 | 2025 | |
| Lucid Diagnostics INC. | $18.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.59 | 2023 | Trintellix |
| Dynavax Technologies Corporation | $17.17 | 2022 | |
| Sanofi Pasteur INC. | $16.64 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.28 | 2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.25 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.